Brotchie JM - Search Results

1

A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.

Lee J, Di Marzo V, Brotchie JM. Lee J, et al. Among authors: brotchie jm. Neuropharmacology. 2006 Sep;51(3):557-65. doi: 10.1016/j.neuropharm.2006.04.016. Epub 2006 Jun 30. Neuropharmacology. 2006. PMID: 16806299

2

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.

Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Di Marzo V, et al. Among authors: brotchie jm. FASEB J. 2000 Jul;14(10):1432-8. doi: 10.1096/fj.14.10.1432. FASEB J. 2000. PMID: 10877836

3

CB1 cannabinoid receptor signalling in Parkinson's disease.

Brotchie JM. Brotchie JM. Curr Opin Pharmacol. 2003 Feb;3(1):54-61. doi: 10.1016/s1471-4892(02)00011-5. Curr Opin Pharmacol. 2003. PMID: 12550742 Review.

4

Levodopa-induced dyskinesia in Parkinson's disease.

Brotchie JM, Lee J, Venderova K. Brotchie JM, et al. J Neural Transm (Vienna). 2005 Mar;112(3):359-91. doi: 10.1007/s00702-004-0251-7. Epub 2004 Dec 22. J Neural Transm (Vienna). 2005. PMID: 15614429 Review.

5

A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.

Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM. Johnston TH, et al. Among authors: brotchie jm. Exp Neurol. 2005 Feb;191(2):243-50. doi: 10.1016/j.expneurol.2004.10.002. Exp Neurol. 2005. PMID: 15649479

6

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.

van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM. van der Stelt M, et al. Among authors: brotchie jm. FASEB J. 2005 Jul;19(9):1140-2. doi: 10.1096/fj.04-3010fje. Epub 2005 May 13. FASEB J. 2005. PMID: 15894565

7

Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.

Visanji NP, Millan MJ, Brotchie JM. Visanji NP, et al. Among authors: brotchie jm. Exp Neurol. 2006 Nov;202(1):85-92. doi: 10.1016/j.expneurol.2006.05.016. Epub 2006 Jun 30. Exp Neurol. 2006. PMID: 16814282

8

Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.

Lee J, Gomez-Ramirez J, Johnston TH, Visanji N, Brotchie JM. Lee J, et al. Among authors: brotchie jm. Synapse. 2008 Apr;62(4):310-3. doi: 10.1002/syn.20481. Synapse. 2008. PMID: 18241048

9

Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.

Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM. Johnston TH, et al. Among authors: brotchie jm. J Pharmacol Exp Ther. 2011 Feb;336(2):423-30. doi: 10.1124/jpet.110.169532. Epub 2010 Oct 21. J Pharmacol Exp Ther. 2011. PMID: 20966038

10

A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.

Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong-Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez-Ramirez J, Lee J, Fox SH, Martin-Iverson M, Nash JE, Piggott MJ, Brotchie JM. Johnston TH, et al. Among authors: brotchie jm. FASEB J. 2012 May;26(5):2154-63. doi: 10.1096/fj.11-195016. Epub 2012 Feb 17. FASEB J. 2012. PMID: 22345403

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

212 results

Search Page